Editas Medicine Executive Chairman James Mullen to not seek re-election; Board adopts amended bylaws

Editas Medicine, Inc.

James C. Mullen, Executive Chairman and former CEO, will not stand for re-election at the 2023 Annual Meeting.
Mullen will continue as Executive Chairman until the 2023 Annual Meeting; cites best practice for former CEOs to rotate off board.
Board approved amended and restated bylaws on March 10, 2023, conforming to recent DGCL amendments and universal proxy rules (Rule 14a-19).
Amended bylaws require additional disclosures for stockholder nominations and allow company to disregard nominations if Rule 14a-19 requirements not met.
Other updates include technical changes to remote meeting adjournment and stockholder list availability.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James C. Mullen

Executive Chairman of the Board

EDIT · Editas Medicine, Inc.

Filed: March 14, 2023, 7:59 PM ET

On March 8, 2023, James C. Mullen, the Executive Chairman of the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James C. Mullen departed as Executive Chairman of the Board at Editas Medicine, Inc..

Action: does not intend to seek re-election as a director
Role: Executive Chairman of the Board

Exact text from the filing

On March 8, 2023, James C. Mullen, the Executive Chairman of the Board of Directors (the “Board”) of Editas Medicine, Inc. (the “Company”) notified the Board that he does not intend to seek re-election as a director of the Company when his current term ends at the 2023 Annual Meeting of Stockholders.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Editas Medicine, Inc.: Amended and restated bylaws to conform with recent DGCL amendments and universal proxy rules (effective 2023-03-10).

Change: bylaw amendment
Effective: 2023-03-10

Exact text from the filing

On March 10, 2023, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an amendment and restatement of the Amended and Restated By-Laws of the Company (as so amended and restated, the "Amended and Restated By-Laws").

View on SEC.gov

Browse all governance changes →

Editas Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-003731

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.